Supportive Care in Cancer

, Volume 21, Issue 3, pp 735–748

Nausea still the poor relation in antiemetic therapy? The impact on cancer patients’ quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster

  • Carlo Pirri
  • Evan Bayliss
  • James Trotter
  • Ian N. Olver
  • Paul Katris
  • Peter Drummond
  • Robert Bennett
Original Article
  • 1.2k Downloads

Abstract

Purpose

Despite significant antiemetic advances, almost 50 % of treated cancer patients still experience nausea and vomiting (N&V). The goal of antiemetic therapy—complete prevention of treatment-induced nausea and/or vomiting (TIN+/−V)—remains elusive for several reasons. Potentially, N&V may be part of a symptom cluster where co-occurring symptoms negatively affect antiemetic management. Consequently, we examined TIN+/−V incidence and the impact of nausea, vomiting and symptom cluster(s) containing them, respectively, on patients’ quality of life (QoL) and psychological adjustment across treatment.

Methods

A longitudinal secondary analysis was performed on data from a prospective, observational QoL study involving 200 newly diagnosed cancer patients who underwent combined modality treatment. QoL, psychological adjustment and patient/clinical characteristics were examined at pretreatment, on-treatment (8 weeks) and post-treatment.

Results

Overall, 62 % of patients experienced TIN+/−V, with TIN (60 %) doubling TIV incidence (27 %). Exploratory factor analyses of QoL scores at each treatment time point identified a recurrent gastrointestinal symptom cluster comprising nausea, vomiting and appetite loss. Approximately two thirds of patients reported co-occurrence of all three symptoms, which exerted synergistic effects of multiplicative proportions on overall QoL. Patients who reported co-occurrence of these symptoms during treatment experienced significantly greater QoL impairment (physical, role and social functioning, fatigue, N&V, appetite loss, overall physical health, overall QOL) and psychological distress (cancer distress, premorbid neuroticism) than those unaffected (0.001 > p ≤ 0.05). Moreover, nausea was more pervasive than vomiting or appetite loss across treatment and had a greater impact on overall QoL. While antiemetic therapy was effective for vomiting and helped prevent/relieve associated appetite loss, the benefits for appetite loss were seemingly constrained by its failure to exert adequate control over nausea in many patients.

Conclusions

TIN+/−V still represents a very major concern for patients. Uncontrolled TIN+/−V often results in significant appetite and weight loss, leading to increased risk for malnutrition. Malnutrition and weight loss, in turn, are associated with poorer prognosis, treatment tolerance and response, performance status, QoL and survival. Consequently, a multiple symptom intervention approach focusing on N&V as core symptoms is recommended. Clinicians should genuinely consider combining essential antiemetic therapies with other evidence-based pharmacological (e.g. nausea: psychotropics, such as olanzapine) and non-pharmacological approaches (e.g. N&V: relaxation) in attempts to not only improve prevention and control of N&V for their patients, but also reduce the synergistic impact of cluster symptoms (e.g. N&V, appetite loss) as a whole and resultant QoL impairment likewise. Where associated symptoms are not adequately controlled by these antiemetic-based interventions, targeted evidence-based strategies should be supplemented.

Keywords

Nausea Vomiting Chemotherapy Cancer Symptom cluster Quality of life Psychological Anorexia Radiotherapy Surgery Non-pharmacological 

Supplementary material

520_2012_1574_MOESM1_ESM.pdf (264 kb)
ESM 1(PDF 263 kb)

References

  1. 1.
    Ballatori E, Roila F, Ruggeri B, Betti M, Sarti S, Soru G, Cruciani G, Di Maio M, Andrea B, Deuson RR (2007) The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer 15:179–185PubMedCrossRefGoogle Scholar
  2. 2.
    The Italian Group for Antiemetic Research in Radiotherapy (IGARR) (1999) Radiation-induced emesis: a prospective observational multicenter Italian trial. Int Radiat Oncol Biol Phys 44:619–625CrossRefGoogle Scholar
  3. 3.
    Booth CM, Clemons M, Dranitsaris G, Joy A, Young S, Callaghan W, Trudeau M, Petrella T (2007) Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study. J Support Oncol 5:374–380PubMedGoogle Scholar
  4. 4.
    Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L (1997) Determinants of postchemotherapy nausea and vomiting in patients with cancer. J Clin Oncol 15(1):116–123PubMedGoogle Scholar
  5. 5.
    Molassiotis A, Yam BMC, Yung H, Chan FYC, Mok TSK (2002) Pretreatment factors predicting the development of postchemotherapy nausea and vomiting in Chinese breast cancer patients. Support Care Cancer 10:139–145PubMedCrossRefGoogle Scholar
  6. 6.
    Djärv T, Lagergren J, Blazeby JM, Lagergren P (2008) Long-term health-related quality of life following surgery for oesophageal cancer. Br J Surg 95(9):1121–1126PubMedCrossRefGoogle Scholar
  7. 7.
    Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, ESMO/MASCC Guidelines Working Group (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243PubMedCrossRefGoogle Scholar
  8. 8.
    Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24(27):4472–4478PubMedCrossRefGoogle Scholar
  9. 9.
    Ballatori E, Roila F, Ruggeri B, Porrozzi S, Iannopollo M, Soru G, Cruciani G, Daniele B, Locatelli MC, Pellissier J, Deuson R (2007) The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer 15(1):31–38PubMedCrossRefGoogle Scholar
  10. 10.
    Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting—incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497–503PubMedCrossRefGoogle Scholar
  11. 11.
    Tina Shih Y, Xu Y, Elting LS (2007) Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer 110(3):678–685PubMedCrossRefGoogle Scholar
  12. 12.
    Ballatori E, Roila F (2003) Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 1:46PubMedCrossRefGoogle Scholar
  13. 13.
    Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J (2011) Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population. Support Care Cancer 19(6):843–851PubMedCrossRefGoogle Scholar
  14. 14.
    Martin CG, Rubenstein EB, Elting LS, Kim YJ, Osoba D (2003) Measuring chemotherapy-induced nausea and emesis. Cancer 98(3):645–655PubMedCrossRefGoogle Scholar
  15. 15.
    Saxby C, Ackroyd R, Callin S, Mayland C, Kite S (2007) How should we measure emesis in palliative care? Palliat Med 21(5):369–383PubMedCrossRefGoogle Scholar
  16. 16.
    Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29(31):4189–4198PubMedCrossRefGoogle Scholar
  17. 17.
    Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, McNulty R, Nabati L, Todaro B, Urba S, Yowell S, National comprehensive Cancer Network (NCCN) (2007) Antiemesis. J Natl Compr Canc Netw 5(1):12–33PubMedGoogle Scholar
  18. 18.
    Molassiotis A, Saunders MP, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C (2008) A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16:201–208PubMedCrossRefGoogle Scholar
  19. 19.
    Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics: perception versus reality. Cancer 100:2261–2268PubMedCrossRefGoogle Scholar
  20. 20.
    Kim HJ, McGuire DB, Tulman L, Barsevick AM (2005) Symptom clusters: concept analysis and clinical implications for cancer nursing. Cancer Nurs 28(4):270–282PubMedCrossRefGoogle Scholar
  21. 21.
    Molassiotis A, Wengström Y, Kearney N (2010) Symptom cluster patterns during the first year after diagnosis with cancer. J Pain Symptom Manag 39(5):847–858CrossRefGoogle Scholar
  22. 22.
    Wilson J, Plourde JY, Marshall D, Yoshida S, Chow W, Harsanyi Z, Pearen S, Darke A (2002) Long-term safety and clinical effectiveness of controlled-release metoclopramide in cancer-associated dyspepsia syndrome: a multicentre evaluation. J Palliat Care 18(2):84–91PubMedGoogle Scholar
  23. 23.
    Pirri C, Katris P, Trotter J, Bayliss E, Bennett R, Drummond P (2011) Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer 19(10):1549–1563PubMedCrossRefGoogle Scholar
  24. 24.
    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376PubMedCrossRefGoogle Scholar
  25. 25.
    Ringdal GL, Ringdal K (1993) Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogenous diagnoses. Qual Life Res 2:129–140PubMedCrossRefGoogle Scholar
  26. 26.
    Selby PJ, Chapman JAW, Etazadi-Amoli J, Boyd NF (1984) The development of a method for assessing quality of life of cancer patients. Br J Cancer 50:13–22PubMedCrossRefGoogle Scholar
  27. 27.
    Beck AT, Beck RW (1972) Screening depressed patients in family practice: a rapid technic. Postgrad Med 52:81–85PubMedGoogle Scholar
  28. 28.
    Horowitz M, Wilner N, Alvarez W (1979) Impact of Event Scale: a measure of subjective stress. Psychosom Med 41:209–218PubMedGoogle Scholar
  29. 29.
    Eysenck HJ, Eysenck SBG (1991) Manual of the Eysenck Personality Questionnaire (revised). Hodder & Stoughton, LondonGoogle Scholar
  30. 30.
    Tabachnick BG, Fidell LS (2007) Using multivariate statistics (fifth edition). Allyn & Bacon, BostonGoogle Scholar
  31. 31.
    Kirkova J, Walsh D (2007) Cancer symptom clusters—a dynamic construct. Support Care Cancer 15(9):1011–1013PubMedCrossRefGoogle Scholar
  32. 32.
    Field A (2009) Discovering statistics using SPSS (third edition). Sage, LondonGoogle Scholar
  33. 33.
    Threlfall TJ, Thompson JR (2000) Cancer incidence and mortality in western Australia, 1998: a report of the western Australian cancer registry. Health Department of Western Australia, PerthGoogle Scholar
  34. 34.
    Cheng KK, Lee DT (2011) Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. Crit Rev Oncol Hematol 78(2):127–137PubMedCrossRefGoogle Scholar
  35. 35.
    Gift AG, Jablonski A, Stommel M, Given CW (2004) Symptom clusters in elderly patients with lung cancer. Oncol Nurs Forum 31(2):203–210CrossRefGoogle Scholar
  36. 36.
    Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5(4):307–313PubMedCrossRefGoogle Scholar
  37. 37.
    Chen ML, Lin CC (2007) Cancer symptom clusters: a validation study. J Pain Symptom Manag 34:590–599CrossRefGoogle Scholar
  38. 38.
    Wang SY, Tsai CM, Chen BC, Lin CH, Lin CC (2008) Symptom clusters and relationships to symptom interference with daily life in Taiwanese lung cancer patients. J Pain Symptom Manag 35:258–266CrossRefGoogle Scholar
  39. 39.
    Molassiotis A, Farrell C, Bourne K, Brearley SG, Pilling M (2012) An exploratory study to clarify the cluster of symptoms predictive of nausea using random forest modelling. J Pain Symptom Manag. doi:10.1016/j.jpainsymman.2011.11.003
  40. 40.
    Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y (2003) Japanese version of the MD Anderson Symptom Inventory: a validation study. J Pain Symptom Manag 26:1093–1104CrossRefGoogle Scholar
  41. 41.
    Evangelista AL, Santos EM (2012) Cluster of symptoms in women with breast cancer treated with curative intent. Support Care Cancer 20(7):1499–1550PubMedCrossRefGoogle Scholar
  42. 42.
    Kim HJ, Barsevick AM, Tulman L, McDermott PA (2008) Treatment-related symptom clusters in breast cancer: a secondary analysis. J Pain Symptom Manag 36:468–479CrossRefGoogle Scholar
  43. 43.
    Miaskowski C, Aouizerat BE, Dodd M, Cooper B (2007) Conceptual issues in symptom clusters research and their implications for quality-of-life assessment in patients with cancer. J Natl Cancer Inst Monogr 37:39–46PubMedCrossRefGoogle Scholar
  44. 44.
    Aktas A, Walsh D, Rybicki L (2010) Symptom clusters: myth or reality? Palliat Med 24(4):373–385PubMedCrossRefGoogle Scholar
  45. 45.
    Foubert J, Vaessen G (2005) Nausea: the neglected symptom? Eur J Oncol Nurs 9:21–32PubMedCrossRefGoogle Scholar
  46. 46.
    Bergkvist K, Wengström Y (2006) Symptom experiences during chemotherapy treatment–with focus on nausea and vomiting. Eur J Oncol Nurs 10(1):21–29PubMedCrossRefGoogle Scholar
  47. 47.
    Molassiotis A, Stricker CT, Eaby B, Velders L, Coventry PA (2008) Understanding the concept of chemotherapy-related nausea: the patient experience. Eur J Cancer Care 17:444–453CrossRefGoogle Scholar
  48. 48.
    Nitenberg G, Raynard B (2000) Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol 34(3):137–168PubMedCrossRefGoogle Scholar
  49. 49.
    Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9(5):188–195PubMedCrossRefGoogle Scholar
  50. 50.
    Licup N (2010) Olanzapine for nausea and vomiting. Am J Hosp Palliat Care 27(6):432–434PubMedCrossRefGoogle Scholar
  51. 51.
    Perwitasari DA, Gelderblom H, Atthobari J, Mustofa M, Dwiprahasto I, Nortier JW, Guchelaar HJ (2011) Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm 33(1):33–43PubMedCrossRefGoogle Scholar
  52. 52.
    Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C, Aranda S (2008) Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol 26(34):5618–5629PubMedCrossRefGoogle Scholar
  53. 53.
    Dileo C (2006) Effects of music and music therapy on medical patients: a meta-analysis of the research and implications for the future. J Soc Integr Oncol 4(2):67–70PubMedCrossRefGoogle Scholar
  54. 54.
    Richardson J, Smith JE, McCall G, Richardson A, Pilkington K, Kirsch I (2007) Hypnosis for nausea and vomiting in cancer chemotherapy: a systematic review of the research evidence. Eur J Cancer Care (Engl) 16(5):402–412CrossRefGoogle Scholar
  55. 55.
    Ezzo JM, Richardson MA, Vickers A, Allen C, Dibble SL, Issell BF, Lao L, Pearl M, Ramirez G, Roscoe JA, Shen J, Shivnan JC, Streitberger K, Treish I, Zhang G (2006) Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting (review). Cochrane Database Syst Rev 2:CD002285PubMedGoogle Scholar
  56. 56.
    Adams LA, Shepard N, Caruso RA, Norling MJ, Belansky H, Cunningham RS (2009) Putting evidence into practice: evidence-based interventions to prevent and manage anorexia. Clin J Oncol Nurs 13(1):95–102PubMedCrossRefGoogle Scholar
  57. 57.
    Berenstein EG, Ortiz Z (2005) Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2:CD004310PubMedGoogle Scholar
  58. 58.
    Navari RM, Brenner MC (2010) Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer 18(8):951–956PubMedCrossRefGoogle Scholar
  59. 59.
    Molassiotis A, Borjeson S (2006) Nausea and vomiting. In: Kearney N, Richardson A (eds) Nursing patients with cancer: Principles and practice. Elsevier, Oxford, pp 415–438Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Carlo Pirri
    • 1
  • Evan Bayliss
    • 2
  • James Trotter
    • 3
  • Ian N. Olver
    • 4
    • 5
  • Paul Katris
    • 6
  • Peter Drummond
    • 1
  • Robert Bennett
    • 1
  1. 1.Faculty of Health SciencesMurdoch UniversityMurdochAustralia
  2. 2.Department of Medical OncologyRoyal Perth HospitalPerthAustralia
  3. 3.Medicine and Pharmacology Royal Perth Hospital UnitUniversity of Western AustraliaCrawleyAustralia
  4. 4.Cancer Council AustraliaSydneyAustralia
  5. 5.Discipline and School of MedicineUniversity of AdelaideAdelaideAustralia
  6. 6.Western Australian Clinical Oncology GroupWest PerthAustralia

Personalised recommendations